. Hl, Drug interactions in the hematopoietic stem cell transplant (HSCT) recipient: what every transplanter needs to know, Bone Marrow Transplant, vol.33, pp.137-52, 2004.

, J Oncol Pharm Pract

R. B. Guastaldi, A. M. Reis, A. Figueras, and S. R. Secoli, Prevalence of potential drug-drug interactions in bone marrow transplant patients, Int J Clin Pharm, vol.33, pp.1002-1009, 2011.

M. Hadjibabaie, S. Badri, S. Ataei, A. H. Moslehi, I. Karimzadeh et al., Potential drug-drug interactions at a referral hematology-oncology ward in Iran: a cross-sectional study, Cancer Chemother Pharmacol, vol.71, pp.1619-1646, 2013.

S. Gholaminezhad, M. Hadjibabaie, K. Gholami, M. R. Javadi, M. Radfar et al., Pattern and associated factors of potential drug-drug interactions in both pre-and early post-hematopoietic stem cell transplantation stages at a, 2014.

, Ann Hematol, vol.93, pp.1913-1935

L. Schaefer, C. Keinki, M. Baron-von-osthoff, and J. Huebner, Potential Interactions of Medication Prescribed in Discharge Letters from a Clinic for Hematology and Oncology, 2018.

, Oncol Res Treat, vol.41, pp.200-205

D. D. -trevisan, J. B. Silva, H. C. Oliveira, S. R. Secoli, and M. H. Lima, Prevalence and clinical significance of potential drug-drug interaction in hematopoietic stem cell transplantation, Cancer Chemother Pharmacol, vol.75, pp.393-400, 2015.

K. Arnaout, N. Patel, M. Jain, J. El-amm, F. Amro et al., Complications of allogeneic hematopoietic stem cell transplantation, Cancer Invest, vol.32, pp.349-62, 2014.

E. A. Hoste, S. M. Bagshaw, R. Bellomo, C. M. Cely, R. Colman et al., Epidemiology of acute kidney injury in critically ill patients: the multinational AKI-EPI study, Glomerular Filtration Rate and Impact on Long-Term Survival among Adults after Hematopoietic Cell Transplantation: A Prospective Cohort Study, vol.41, 2015.

, Clin J Am Soc Nephrol, 2018.

A. S. -levey, L. A. Stevens, C. H. Schmid, Y. L. Zhang, A. F. Castro et al., A new equation to estimate glomerular filtration rate, 2009.

, Ann Intern Med, vol.150, pp.604-616

B. Farzanegan, M. Alehashem, M. Bastani, and S. Baniasadi, Clinical Practice Guidelines For Chronic Kidney Disease: Evaluation, Classification and Stratification National Kidney Foundation, Kidney Disease Outcomes Quality Initiative, vol.55, pp.132-138, 2002.

E. V. Uijtendaal, L. L. Van-harssel, G. W. Hugenholtz, E. M. Kuck, J. E. Zwart-van-rijkom et al., Analysis of potential drug-drug interactions in medical intensive care unit patients, Pharmacotherapy, vol.34, pp.213-222, 2014.

D. Vanham, A. Spinewine, P. Hantson, X. Wittebole, D. Wouters et al., Drug-drug interactions in the intensive care unit: Do they really matter?, J Crit Care, vol.38, pp.97-103, 2017.

M. Ando, K. Ohashi, H. Akiyama, H. Sakamaki, T. Morito et al., Chronic kidney disease in long-term survivors of myeloablative allogeneic haematopoietic cell transplantation: prevalence and risk factors, Nephrol Dial Transplant, vol.25, pp.278-82, 2010.

A. -kogon and S. Hingorani, Acute kidney injury in hematopoietic cell transplantation, Semin Nephrol, vol.30, pp.615-641, 2010.

S. H. -binnenmars, R. S. Hijmans, G. Navis, and M. H. De-borst, Biomarkers of Renal Function: Towards Clinical Actionability, 2017.

, Clin Pharmacol Ther, vol.102, pp.481-492

O. -rewa and S. M. Bagshaw, Acute kidney injury-epidemiology, outcomes and economics, Nat Rev Nephrol, vol.10, pp.193-207, 2014.

L. Awdishu and R. L. Mehta, The 6R's of drug induced nephrotoxicity, BMC Nephrol, vol.18, p.124, 2017.

-. S. , Food and Drug Administration. Drug Development and Drug Interactions: Table of Substrates